Novo Nordisk CEO: We are a cardiometabolic powerhouse
Speakers
Mike Doustdar
— CEO, Novo Nordisk
Summary
Novo Nordisk CEO Mike Doustdar discusses the company's pipeline and strategy at the ADA 2026 Scientific Sessions. He highlights next-generation obesity and diabetes therapies, including oral peptides and triple agonists, and reaffirms Novo's identity as a cardiometabolic powerhouse. He also explains the ongoing transformation to regain competitive edge and deliver long-term shareholder value.
- Novo CEO Mike Doustdar interviewed at ADA 2026 Scientific Sessions.
- Pipeline includes next-gen drugs like UBT251 (19.7% weight loss in 24 weeks) and oral peptide pills.
- Company aims to lead in cardiometabolic diseases across diabetes, obesity, MASH, and CKD.
- Novo is accelerating R&D and exploring in-house and external assets to build broadest portfolio.
- CEO emphasizes long-term patient focus, transformation, and cost cuts to improve agility.
- Goal is to regain leadership after Wegovy lost ground to Lilly's Zepbound.
- Novo remains a focused cardiometabolic company with adjacencies in rare disease and endocrinology.
Ideas
Novo Nordisk pipeline drives cardiometabolic leadership.
Novo Nordisk has a deep pipeline of next-generation cardiometabolic drugs, including oral peptides, triple agonists like UBT251 showing 19.7% weight loss in 24 weeks, and specialty products for MASH and CKD. The company is committed to building the broadest portfolio for 2 billion patients, accelerating R&D, and regaining leadership in the obesity/diabetes market after Wegovy fell behind Zepbound. The CEO's long-term vision and transformation efforts position the company for sustained growth and shareholder value.
Up Next
This CNBC video, published June 09, 2026, features Mike Doustdar discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: Mike Doustdar · Tickers: NVO